Manufacturing: Page 36
-
Daiichi Sankyo to invest $135M in ADC manufacturing expansion
Antibody drug conjugates are a big part of the Japanese pharma's early-stage pipeline in oncology — an area in which the company hopes to become more competitive.
By Ned Pagliarulo • April 27, 2017 -
LabCorp bolsters biologics capacity of Covance unit in UK
Higher demand for biologic drugs led to the expansion, the lab and drug development giant said.
By Suzanne Elvidge • April 27, 2017 -
Biopharma opening up to new ways of partnering on R&D
A report from Deloitte found the number of early-stage, science-focused collaborations to have increased rapidly over the past 10 years.
By Ned Pagliarulo • April 20, 2017 -
FDA explains why it rejected AstraZeneca's ZS-9
The agency released a Form 483 on Wednesday detailing the manufacturing faux pas that led to the hyperkalemia drug's dismissal for a second time.
By Jacob Bell • April 20, 2017 -
Fujifilm invests $130M in manufacturing expansions
The Japanese film company turned pharma developer is planning expansions at sites in Texas and the U.K.
By Jacob Bell • April 20, 2017 -
Cobra invests $19M to boost gene therapy manufacturing
As more cell and gene therapies near regulatory review and commercial use, contractors are ramping up their production capabilities to meet demand.
By Suzanne Elvidge • April 20, 2017 -
GE acquires British cold chain specialist, deepening cell therapy push
The tech and manufacturing giant is building up its manufacturing and delivery capabilities in cell therapy, aiming to capitalize on the growing market.
By Ned Pagliarulo • April 13, 2017 -
In more bad news, Mylan receives CRL for Indian facility
The FDA criticized the drugmaker for not addressing the root cause of many of the manufacturing violations at its Maharashtra, India, plant.
By Jacob Bell • April 13, 2017 -
FDA warns Teva over violations at China plant
The drugmaker said it is already taking corrective action to fix the regulator's concerns, which are related to manufacturing control and sampling processes.
By Ned Pagliarulo • April 13, 2017 -
Could organs on a microchip help test for toxins? The FDA wants to find out
The regulator will collaborate with the private Emulate, Inc. to test the company's organ-on-a-chip technology as a potential toxicology testing platform.
By Suzanne Elvidge • April 13, 2017 -
Generics maker Akorn jumps on Fresenius takeout talks
After rumors swirl, Fresenius Kabi and Akorn confirm that they are in acquisition talks.
By Suzanne Elvidge • April 10, 2017 -
Dr. Reddy's hit with another Form 483
It's the latest in a string of manufacturing problems the drug developer has faced over the past few years.
By Jacob Bell • April 6, 2017 -
New guidelines to make China a more drug-friendly market
CFDA announced draft guidelines that would allow Phase I trials in China to encourage simultaneous development alongside global trials.
By Tamra Sami • April 3, 2017 -
Warp Drive Bio teams up with GSK, taking aim at 'undruggable' targets
Together, the two companies hope to build a library of as many as 200 million souped-up compounds to screen against historically un-targetable proteins.
By Ned Pagliarulo • March 30, 2017 -
Agenus trims staff, narrows focus in restructuring
The biotech will close a facility in Basel, Switzerland as it consolidates to push two checkpoint inhibitor candidates through clinical development.
By Ned Pagliarulo • March 30, 2017 -
Novartis, Aurobindo drugs hit by EMA-advised suspensions
The agency claims four years of bioequivalence data from an Indian contract research organization were not satisfactory, and released a 32-page list of drugs that could face suspension.
By Jacob Bell • March 30, 2017 -
Lilly touts $850M manufacturing investment as CEO stumps for tax reform
The Indianapolis drugmaker plans to continue expanding its diabetes manufacturing, announcing details to its 2017 plans in a move likely to please President Trump.
By Ned Pagliarulo • March 24, 2017 -
FDA
Control over production data still tripping up foreign drug manufacturers with FDA
Warning letters sent to two drugmakers in India and China show a lack of data controls and failure to investigate test results are still common problems with foreign suppliers.
By Ned Pagliarulo • March 23, 2017 -
FDA bans Divi's Labs plant, dealing another blow to India's quality credibility
Efforts by the Indian drugmaker to right manufacturing violations clearly haven't been enough to keep it off the agency's bad side.
By Jacob Bell • March 23, 2017 -
Valeant hopes for August approval of eye drug
Manufacturing problems at a Tampa, FL facility tripped up Valeant's application last year, but, with a PDUFA date now set, those issues look to be resolved.
By Ned Pagliarulo • March 23, 2017 -
Who stands to benefit from Mylan's EpiPen recall?
A voluntary recall of Mylan's EpiPen could mean trouble for the drugmaker and a boon for its competitors.
By Suzanne Elvidge • March 23, 2017 -
FDA hands AstraZeneca's ZS-9 another setback
The agency issued a complete response letter to AstraZeneca for its hyperkalemia drug, giving it a second rejection.
By Jacob Bell • March 17, 2017 -
FDA warns two manufacturers from China, India for GMP lapses
Continuing a trend of stepped-up oversight, drug manufacturers from India and China have been frequently tripped up by FDA standards.
By Ned Pagliarulo • March 16, 2017 -
Takeda teams up with venture firm on drug discovery unit
The Japanese pharma has been narrowing its focus to three core therapeutic areas as part of a broader restructuring aimed at revitalizing the veteran company.
By Ned Pagliarulo • March 16, 2017 -
Sun Pharma gets ray of good manufacturing news
While some reforms still need to be addressed, the FDA intends to lift a ban that has been in place for more than three years on the company's Mohali facility.
By Jacob Bell • March 16, 2017
Previous
